Impact of Leadership Change at the FDA

This chapter explores the potential effects of a leadership shift at the FDA, influenced by RFK Jr., particularly concerning drug approval processes like mifepristone and alternative therapies. It raises concerns about public trust in health systems, implications for NIH funding, and the politicization of healthcare regulations. The conversation also touches on controversial health topics like raw milk, reflecting broader societal movements and their impact on FDA policies.